FDA clinical trial tables

June 17, 2014 – 05:25 am

FDA Statement on recently terminated clinical trial with Doribax

The U.S. Food and Drug Administration (FDA) is informing the public that a recent clinical trial with Doribax (doripenem) was stopped early because of significant safety concerns. This trial, which was evaluating the effects of Doribax on treatment of patients with ventilator-associated pneumonia, demonstrated excess mortality and a numerically poorer clinical cure rate among subjects treated with Doribax compared to those treated with imipenem-cilastatin. FDA is reviewing the trial results and will communicate any new information that results from this investigation.

Healthcare professionals should be aware that Doribax is not approved to treat any type of pneumonia, nor is it approved for doses greater than 500 mg every eight hours.

Doribax is still considered safe and effective for its approved indications-treatment of adults with complicated intra-abdominal infections and complicated urinary tract infections including pyelonephritis. The recommended dose of Doribax is 500 mg every eight hours intravenously, given over 1 hour, for a total of 5-14 days (depending on indication) in adults.

According to Janssen Research and Development LLC (Doribax's manufacturer), Table 1 below shows the interim results for both clinical cure rates and 28-day all-cause mortality rates for the Microbiological Intent-to-Treat (MITT) population and the Microbiologically Evaluable (ME) population.

Table 1. Summary of Clinical Cure Rates and All-Cause 28-Day Mortality Rate

Analysis Population	Doripenem Group %	Imipenem Group %	Difference %	2-sided 95% CI %
Clinical Cure Rates
MITT	45.6	56.8	-11.2	-26.3 to 3.8
ME	49.1	66.1	-17	-34.7 to 0.8

All Cause 28-day Mortality Rate (MITT)	21.5	14.8	6.7	-5.0 to 18.5

Source: www.fda.gov

NKF & FDA Conference on Alternative Endpoints for Clinical ...

Oramed Announces Successful FDA Phase 2a Clinical Trial ...

BMC Medical Research Methodology at the 35th Annual Conference of the .. — BMC Pediatrics
The conference will focus on issues such as design and analysis of clinical trials, methods in biostatistics and development of clinical prediction models.

Nutrigold CoQ10 Gold (High Absorption) (Clinically-proven KanekaQ10), 100 mg, 120 softgels
Health and Beauty (Nutrex Research, Inc.)

Nutrigold s High Absorption CoQ10 Gold sets the Gold Standard for CoQ10 supplements
Features World s #1 KanekaQ10 - The purest, 100% natural, all-trans bio-identical, and most researched CoQ10 for over 30 years
Clinically-proven superior bioavailability and absorption with patented BioPerine®
In the last 30 years, the vast majority of clinical research that confirmed CoQ10 s benefits, used this same exact CoQ10
100mg CoQ10 per Softgel. 120 Softgels per Bottle (GMO-free, Allergen-free, Kosher Certified CoQ10)

Popular Q&A

Does the European clinical trials directive really improve clinical trial approval time?

To facilitate and improve clinical research within Europe, the European Union (EU) adopted in 2001 the Clinical Trials Directive (EUCTD). The aim of this study was to compare duration between submission of a clinical drug trial application and approval by regulatory authorities in EU countries regulated by EUCTD vs. EU countries regulated by local legislation and, second, to compare the duration of regulatory approval in Europe vs. the USA and Australia.